Anti-IL-1 agents, types of studies supporting the maximum evidence level for their use, and common pediatric and adult doses given in the main monogenic autoinflammatory diseases (crFMF, TRAPS, HIDS/MKD, and CAPS) and PFAPA syndrome. This evidence concerns the gene IL1A and cryopyrin-associated periodic syndrome.